New Delhi: The Congress has recommended cricketer Sachin Tendulkar's name for the Rajya Sabha and is now waiting for Tendulkar to respond to the same, according to sources. Sources say that Sachin Tendulkar may not accept the nomination. However, an official announcement was awaited.
Sources say that the Congress has offered to nominate him in the President's quota. Tendulkar along with his wife Anjali met Congress President Sonia Gandhi at her 10 Janpath Residence in New Delhi.
Although officially the Congress said that Sonia wanted to meet Tendulkar and personally congratulate him on achieving the historic achievement of scoring 100 international centuries, but sources say the main agenda was his nomination for the Rajya Sabha.
Sachin has accepted a nomination for Rajya Sabha, according to the update from sources. He is the first active sportsperson and cricketer to have been nominated to the Rajya Sabha.
Tendulkar along with his wife Anjali met Congress President Sonia Gandhi at her 10 Janpath residence in New Delhi.
Although officially the Congress said that Sonia wanted to meet Tendulkar and personally congratulate him on achieving the historic achievement of scoring 100 international centuries, but sources say the main agenda was his nomination for the Rajya Sabha.
Reacting to the reports of Sachin Tendulkar's proposed nomination, BJP leader Najma Heptulla said, "We are very happy that Tendulkar's name has been proposed for the Rajya Sabha."
"Tendulkar is a great player, we are proud of him. If he is being nominated, surely he would devote some time to Parliament," BJP spokesperson Ravi Shankar Prasad said.
However, the proposal didn't go well with people from the cricket fraternity. Cricket analyst Harsha Bhogle said, "I don't think it is the greatest idea. He doesn't have the experience of governing or doing social work. People are trying to gain mileage out of Tendulkar."
Meanwhile, the Board of Control of Cricket in India (BCCI) welcomed the government's nomination of Tendulkar as a member of the Rajya Sabha, saying that the iconic batsman deserves such an honour.
BCCI Chief Administrative Officer Prof. Ratnakar Shetty said that the Board was happy with the government's move. "We (BCCI) are happy that Tendulkar's services as a sportsperson has been recognised. He's been a true ambassador for the country and he deserves it," he said.
In the past, eminent personalities like directors Shyam Benegal, Mrinal Sen and playback singer Lata Mangeshkar had been the nominated members of the Rajya Sabha.
Sources say that the Congress has offered to nominate him in the President's quota. Tendulkar along with his wife Anjali met Congress President Sonia Gandhi at her 10 Janpath Residence in New Delhi.
Although officially the Congress said that Sonia wanted to meet Tendulkar and personally congratulate him on achieving the historic achievement of scoring 100 international centuries, but sources say the main agenda was his nomination for the Rajya Sabha.
Sachin has accepted a nomination for Rajya Sabha, according to the update from sources. He is the first active sportsperson and cricketer to have been nominated to the Rajya Sabha.
Tendulkar along with his wife Anjali met Congress President Sonia Gandhi at her 10 Janpath residence in New Delhi.
Although officially the Congress said that Sonia wanted to meet Tendulkar and personally congratulate him on achieving the historic achievement of scoring 100 international centuries, but sources say the main agenda was his nomination for the Rajya Sabha.
Reacting to the reports of Sachin Tendulkar's proposed nomination, BJP leader Najma Heptulla said, "We are very happy that Tendulkar's name has been proposed for the Rajya Sabha."
"Tendulkar is a great player, we are proud of him. If he is being nominated, surely he would devote some time to Parliament," BJP spokesperson Ravi Shankar Prasad said.
However, the proposal didn't go well with people from the cricket fraternity. Cricket analyst Harsha Bhogle said, "I don't think it is the greatest idea. He doesn't have the experience of governing or doing social work. People are trying to gain mileage out of Tendulkar."
Meanwhile, the Board of Control of Cricket in India (BCCI) welcomed the government's nomination of Tendulkar as a member of the Rajya Sabha, saying that the iconic batsman deserves such an honour.
BCCI Chief Administrative Officer Prof. Ratnakar Shetty said that the Board was happy with the government's move. "We (BCCI) are happy that Tendulkar's services as a sportsperson has been recognised. He's been a true ambassador for the country and he deserves it," he said.
In the past, eminent personalities like directors Shyam Benegal, Mrinal Sen and playback singer Lata Mangeshkar had been the nominated members of the Rajya Sabha.
O2, one of the biggest U.K. Cell phone networks, has realized that it can seize a place in the digital payment revolution by launching its own system...the O2 Wallet. It's a digital charge card system, which you fill up via payments from a traditional credit card, and then you can transfer funds between £1 and £500 between phones and to the websites of over 100 big-name retailers. For now it can't work in stores, but showing the counter-cultural powers of mobile pay the app lets you scan the barcode of an item you like in a store, and then helps you find it cheaper online. Plus NFC capabilities will be added soon to allow in-store purchases. It's clever, and is a taster of bigger things to come, but it's also a demo of how muddied the mobile payment waters are becoming as every enterprise in the race, from operators to phone makers to credit card firms tries to jockey for best position.
It is not news that BlackBerry is lagging behind as far as their operating system is concerned compared to the likes of Android and iOS who have completely dominated the smartphone sphere in recent years. To amend this situation, BlackBerry announced the BlackBerry 10 OS which would put them in contention as a top smartphone manufacturer. Late last year, former Research in Motion CEO stated that the first device running this upcoming operating system would make its first appearance by the end of 2012. However, for those who are eagerly awaiting the BlackBerry 10 OS, it seems that a report by N4BB has some good news as their sources claim that the first handset using this OS will be unveiled by mid-August 2012. This pushes the release date up quite a bit from what was previously believed.
India's mammoth biometrics project, Aadhaar, has been challenged as an expensive undertaking that risked duplicating ID schemes already in place. But a new study suggests that Aadhaar may be on track to reaching its goal of IDing unregistered low-income millions across rural India. A survey of 514,000 households show that 56 percent of Aadhaar enrollees did not have other forms of portable IDs. Lead author Arun Sundararajan from NYU's Stern business school predicts that 300 million Indians without any form of ID would have one by the end of 2012, if signups and enrollments continue in the coming months as expected. "What's important here is that we are not simply seeing people with pre-existing portable ID adding yet another one to their repertoire" Sundararajan said in the release. "Rather, millions of Indians who had no modern form of ID now have one, and this number is growing every month." A form of ID is required to open bank accounts, register for cell phones, and access any kind of government benefit scheme. As enrollment numbers grow--200 million Indians have been enrolled, 170 million have been issued IDs--the Aadhaar system is due to be piloted at banks in 50 districts in India.
HTC and Facebook may be building another phone together, DigiTimes has heard, to launch by Q3 this year. The Android device will have certain Facebook-specific features tucked in. It will be the third phone HTC is working on, after the ChaCha and Salsa. The partnership is an alignment of allies: As Samsung partners with Google for the Nexus series, HTC picks Facebook as a partner.
Facebook is offering Facebookers 6 months' worth of free antivirus software via a new partnership with security champs McAfee, Microsoft, Symantec, Sophos, and TrendMicro. Users can download protection from Facebook's new Antivirus Marketplace, and the antivirus protection won't be confined to user's Facebook pages, rather, the companies will squash web-wide threats. Facebook's massive popularity makes it a target for bad links and spam, something Facebook's been tackling through its partnership with companies like McAfee and Websense. Those security companies scan every link a Facebooker clicks on, and compare it with a "blacklist" of bad sites on their databases. A user is then warned about the site before they can click to proceed. Now, with the free antivirus downloads, it looks like Facebook's taking a broader approach to keeping the social network safe.
Google's just released a new resource for enterprises that are struggling to adapt their business models to address the new mobile technology revolution. In building the Mobile Playbook, Google says it spoke to "hundreds" of companies, and that they "understand that they need to invest in mobile to engage with their customers on this platform. The problem is, most don't know where to start." Hence the HTML5-based resource that Google's put together. It's accessible on tablets, of course, and Google has a vested interest in helping companies go mobile as it supplies the OS behind the majority of the world's smartphones, and also sells billions of mobile ads this way. Keen eyes will spot, however, that Google's example image is of an Apple iPad.
• Amgen (AMGN) Smacks Down $700 Million for Turkey Drugmaker More...
• GlaxoSmithKline (GSK) Insists it is the Best Owner for Human Genome Sciences, Inc. (HGSI) More...
• Targacept, Inc. (TRGT) to Cut 46% Of Workforce After Drug-Trial Setbacks More...
• Gene Ray, Founder of $2.6 Billion Titan Corporation (TTN), Invests in MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.)'s ERC Technology and Joins Advisory Board More...
• Vernalis PLC (VNLPY.PK) and Servier Achieve Research Milestone in Drug Discovery Collaboration More...
• AstraZeneca PLC (AZN) and The Medicines Company (MDCO) Announce Global Collaboration in Acute Ischemic Heart Disease More...
• AtheroNova Inc. (AHRO.OB) Signs Agreement for Development of Clinical Trial Supplies More...
• Integral Molecular, Inc. Announces Lipoparticle Distribution in Japan by Funakoshi Co. More...
• Johnson & Johnson (JNJ) CEO Under Fire for Big Bonuses Amid Scandals More...
• Novartis AG (NVS) Tries More Exec Level OTC Switches More...
• Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer More...
• Zyngenia Recruits David Parkinson, M.D., as Board Member, Clinical Advisory Board Head, and Interim Chief Medical Officer More...
• Threshold Pharmaceuticals, Inc. (THLD) Appoints Robert Simon as Senior Vice President of Regulatory Affairs More...
• Boehringer Ingelheim Corporation's 2011 Profit Jumps 66 Percent More...
• Amgen (AMGN) Posts Strong Drug Sales, Beats Estimates More...
• Amgen (AMGN)'s First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61More...
• Acura Pharmaceuticals, Inc. (ACUR) to Host First Quarter 2012 Financial Results Conference Call on May 2, 2012 More...
• Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) Reports First Quarter 2012 Financial Results and Corporate Updates More...
• ViroPharma Incorporated (VPHM) Loses Bid for Order Blocking Generic Vancocin More...
• Icahn and Amylin Pharmaceuticals, Inc. (AMLN) Have May 10 Hearing for Proxy War More...
• Law Office of Brodsky & Smith, LLC Announces Investigation of Ardea Biosciences, Inc. More...
• Precision BioSciences Files Tenth Patent Infringement Lawsuit Against CELLECTIS SA Related to Meganuclease Technology and Requests Permanent Injunction More...
• Pfizer Consumer Healthcare (PFE) Release: The Advil® Congestion Relief Project Visits St. Louis To Expand Building Space For More Access To Local Family Social Service Program More...
• Ipsen Pursues Its Development in the United States With the Opening of Its New Commercial Headquarters in New Jersey (NJ) More...
• Sanofi (France) (SAN.PA)'s Lemtrada Beats Rebif in MS Face-off More...
• Kythera Biopharmaceuticals Announces Positive Results from Two Pivotal European Phase III Trials of ATX-101 for Reduction of Submental Fat More...
• AVI BioPharma, Inc. (AVII) to Present Additional Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 2012 American Academy of Neurology Annual Meeting More...
• Repligen Corporation (RGEN) Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy More...
• Ablynx Release: Nanobody for Alzheimer's Disease From the Alliance With Boehringer Ingelheim Corporation Moves Closer Towards Phase I Clinical Trials More...
• American Regent, Inc. Initiates Nationwide Voluntary Recall of Epinephrine Injection, USP, 1:1000, 1 mL Ampules Lot #1395 Due to Discoloration and Small Visible Particles More...
• Novartis AG (NVS) Drug SigniforR Gets EU Approval as the First Medication to Treat Patients With Cushing's Disease More...
• Salix Pharmaceuticals, Ltd. (SLXP), Progenics Pharmaceuticals, Inc. (PGNX) Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012 More...
• Fish Oil Could be Therapy for Periodontal Disease, University of South Australia Reveals More...
• Botox Ingredient Has Limited Effect on Headaches, Medical College of Wisconsin Study More...
• Does Fatty Food Impact Marital Stress? Ohio State University Medical Center Study More...
• Signs of Early DNA "Aging" in Abused Kids, Duke University Study More...
• Evaluating the First Drug to Show Improvement in Subtype of Autism, Mount Sinai School of Medicine Study More...
• VistaGen Therapeutics, Inc. Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity More...
• Lpath, Inc. Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab More...
• Metabolix, Inc. Awarded Two U.S. Patents for Technology to Produce Biobased Polymers and Industrial Chemicals More...
• BioLineRx Ltd. Announces Extension of Patent for BCM (BL-1040) by USPTO More...
• Marshall Edwards, Inc. (MSHL) Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating Cancer More...
• Novartis AG (NVS)'s Gilenya Given Final Approval by UK's Cost Agency More...
• PuraMed BioScience Continues to Build Awareness for LipiGesic(R) M Through Media Campaigns More...
• New Products from Abbott Laboratories (ABT)'s EAS(R) Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals More...
• GlaxoSmithKline (GSK) Insists it is the Best Owner for Human Genome Sciences, Inc. (HGSI) More...
• Targacept, Inc. (TRGT) to Cut 46% Of Workforce After Drug-Trial Setbacks More...
• Gene Ray, Founder of $2.6 Billion Titan Corporation (TTN), Invests in MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.)'s ERC Technology and Joins Advisory Board More...
• Vernalis PLC (VNLPY.PK) and Servier Achieve Research Milestone in Drug Discovery Collaboration More...
• AstraZeneca PLC (AZN) and The Medicines Company (MDCO) Announce Global Collaboration in Acute Ischemic Heart Disease More...
• AtheroNova Inc. (AHRO.OB) Signs Agreement for Development of Clinical Trial Supplies More...
• Integral Molecular, Inc. Announces Lipoparticle Distribution in Japan by Funakoshi Co. More...
• Johnson & Johnson (JNJ) CEO Under Fire for Big Bonuses Amid Scandals More...
• Novartis AG (NVS) Tries More Exec Level OTC Switches More...
• Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer More...
• Zyngenia Recruits David Parkinson, M.D., as Board Member, Clinical Advisory Board Head, and Interim Chief Medical Officer More...
• Threshold Pharmaceuticals, Inc. (THLD) Appoints Robert Simon as Senior Vice President of Regulatory Affairs More...
• Boehringer Ingelheim Corporation's 2011 Profit Jumps 66 Percent More...
• Amgen (AMGN) Posts Strong Drug Sales, Beats Estimates More...
• Amgen (AMGN)'s First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61More...
• Acura Pharmaceuticals, Inc. (ACUR) to Host First Quarter 2012 Financial Results Conference Call on May 2, 2012 More...
• Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) Reports First Quarter 2012 Financial Results and Corporate Updates More...
• ViroPharma Incorporated (VPHM) Loses Bid for Order Blocking Generic Vancocin More...
• Icahn and Amylin Pharmaceuticals, Inc. (AMLN) Have May 10 Hearing for Proxy War More...
• Law Office of Brodsky & Smith, LLC Announces Investigation of Ardea Biosciences, Inc. More...
• Precision BioSciences Files Tenth Patent Infringement Lawsuit Against CELLECTIS SA Related to Meganuclease Technology and Requests Permanent Injunction More...
• Pfizer Consumer Healthcare (PFE) Release: The Advil® Congestion Relief Project Visits St. Louis To Expand Building Space For More Access To Local Family Social Service Program More...
• Ipsen Pursues Its Development in the United States With the Opening of Its New Commercial Headquarters in New Jersey (NJ) More...
• Sanofi (France) (SAN.PA)'s Lemtrada Beats Rebif in MS Face-off More...
• Kythera Biopharmaceuticals Announces Positive Results from Two Pivotal European Phase III Trials of ATX-101 for Reduction of Submental Fat More...
• AVI BioPharma, Inc. (AVII) to Present Additional Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 2012 American Academy of Neurology Annual Meeting More...
• Repligen Corporation (RGEN) Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy More...
• Ablynx Release: Nanobody for Alzheimer's Disease From the Alliance With Boehringer Ingelheim Corporation Moves Closer Towards Phase I Clinical Trials More...
• American Regent, Inc. Initiates Nationwide Voluntary Recall of Epinephrine Injection, USP, 1:1000, 1 mL Ampules Lot #1395 Due to Discoloration and Small Visible Particles More...
• Novartis AG (NVS) Drug SigniforR Gets EU Approval as the First Medication to Treat Patients With Cushing's Disease More...
• Salix Pharmaceuticals, Ltd. (SLXP), Progenics Pharmaceuticals, Inc. (PGNX) Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012 More...
• Fish Oil Could be Therapy for Periodontal Disease, University of South Australia Reveals More...
• Botox Ingredient Has Limited Effect on Headaches, Medical College of Wisconsin Study More...
• Does Fatty Food Impact Marital Stress? Ohio State University Medical Center Study More...
• Signs of Early DNA "Aging" in Abused Kids, Duke University Study More...
• Evaluating the First Drug to Show Improvement in Subtype of Autism, Mount Sinai School of Medicine Study More...
• VistaGen Therapeutics, Inc. Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity More...
• Lpath, Inc. Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab More...
• Metabolix, Inc. Awarded Two U.S. Patents for Technology to Produce Biobased Polymers and Industrial Chemicals More...
• BioLineRx Ltd. Announces Extension of Patent for BCM (BL-1040) by USPTO More...
• Marshall Edwards, Inc. (MSHL) Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating Cancer More...
• Novartis AG (NVS)'s Gilenya Given Final Approval by UK's Cost Agency More...
• PuraMed BioScience Continues to Build Awareness for LipiGesic(R) M Through Media Campaigns More...
• New Products from Abbott Laboratories (ABT)'s EAS(R) Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals More...
As this firefly comets through the desert, I gain an appreciation for the smallest, most beautiful thing that paints me a picture out of pure light. How wonderful life seems for a moment.
But it’s no firefly. This is actually a newly developed, self-guiding bullet by Sandia National Laboratories. Designed for contemporary guns, this 4-inch smart bullet steers itself through the air, making 30 precision adjustments per second, to strike a laser-targeted spot over a mile away.
Whereas most bullets spiral through the air, Sandia’s bullet flies balanced, like a miniature airplane. Tiny electromagnetic actuators make micro adjustments to tail fins that slice through the air. And as you can see in that almost-inspiring lead photo, in which an onboard LED traces the bullet’s path, the journey is anything but straight. In fact, the flight path can actually over-correct rather than attempt precision calculations at every turn, and still reach a target that’s over half a mile away within an 8-inch range (by comparison, an unguided bullet could miss by as much as 27 feet). And the longer the flight, the more of these approximate adjustments can be made, meaning that the longer the bullet flies, the more accurate it becomes.
Indeed, the bullet’s entire design has a dark brilliance to it, using a bullet’s primary limitation (range) as its strength. But still, did they need to present it so gorgeously? I’ll never look at another light painting the same way again, knowing that a bullet could take the place of any flashlight in the dark.
But it’s no firefly. This is actually a newly developed, self-guiding bullet by Sandia National Laboratories. Designed for contemporary guns, this 4-inch smart bullet steers itself through the air, making 30 precision adjustments per second, to strike a laser-targeted spot over a mile away.
Whereas most bullets spiral through the air, Sandia’s bullet flies balanced, like a miniature airplane. Tiny electromagnetic actuators make micro adjustments to tail fins that slice through the air. And as you can see in that almost-inspiring lead photo, in which an onboard LED traces the bullet’s path, the journey is anything but straight. In fact, the flight path can actually over-correct rather than attempt precision calculations at every turn, and still reach a target that’s over half a mile away within an 8-inch range (by comparison, an unguided bullet could miss by as much as 27 feet). And the longer the flight, the more of these approximate adjustments can be made, meaning that the longer the bullet flies, the more accurate it becomes.
Indeed, the bullet’s entire design has a dark brilliance to it, using a bullet’s primary limitation (range) as its strength. But still, did they need to present it so gorgeously? I’ll never look at another light painting the same way again, knowing that a bullet could take the place of any flashlight in the dark.
• Novartis AG (NVS) Pushes UK Hospitals to Use $1,000 Drug More...
• Affymax, Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Release: OMONTYS® (Peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United States More...
• Mylan Inc. (MYL) Launches Generic Version of Zyprexa® Tablets More...
• Vertex Pharmaceuticals (MA) (VRTX) Release: INCIVEK (telaprevir) Now Funded for People With Hepatitis C in Quebec and Saskatchewan More...
• Dr. Reddy's Laboratories Ltd. (RDY)'s Announces the Launch of Olanzapine Tablets More...
• Ikaria Inc.'s LUCASSIN® Approved in Australia More...
• Alimera Sciences (ALIM) Release: ILUVIEN® Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema More...
• Biogen Idec, Inc. (Massachusetts) (BIIB) Says Phase III Data Highlight Safety Profile For BG-12 MS Drug; Stock Rises +Up 2.14(1.70%) @ 1:22PM EDT More...
• Sosei Group Corporation's QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149 More...
• Nordion International Announces Europe-Focused Phase III Clinical Trial for TheraSphere® Liver Cancer Treatment More...
• RedHill Biopharma Ltd. Commences a Pivotal Bioequivalence Trial with RHB-103 (An Oral Thin Film for the Treatment of Migraine); Subjects' Recruitment Completed; First Dose Administered; Results Expected within Months More...
• Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase 2 Trial of TSO in Crohn's Disease More...
• Evidence Behind Autism Drugs May Be Biased, University of Michigan Study More...
• Could Caffeine Help Dry Eye? University of Tokyo School of Medicine Study More...
• How to Look Good on Facebook, University of Twente Study More...
• PURE Bioscience (PURE) Announces Positive Research from University of Arkansas More...
• Advanced Cell Technology Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt's Disease Patients in U.S. Trial More...
• NewLink Genetics Receives Notice of Allowance From USPTO for New Patent Broadly Covering Its D-1MT IDO Pathway Inhibitor More...
• MediciNova, Inc. Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain More...
• Merck KGaA (MKGAF.PK) Slashes 580 Jobs Amid Swiss HQs Shutdown More...
• Unipharma to Add 44 Jobs in New York More...
• Argos Therapeutics, Inc. Raises $25 Million Series D Financing More...
• miRagen Therapeutics Secures $20 Million Series B Financing More...
• Watson Pharmaceuticals, Inc. (WPI) May Pay $6 Billion Actavis More...
• Bausch & Lomb and ISTA Pharmaceuticals, Inc. (ISTA) Announce Early Termination of Hart-Scott-Rodino Waiting Period More...
• IMS Health (RX) Expands Services in Pharma R&D With Acquisition of DecisionView More...
• US Clinical Laboratories Announces Houston Acquisition More...
• Bayer AG (BAY.F) to Develop Cancer Treatment With Amgen (AMGN) More...
• ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development More...
• Northwest Biotherapeutics (NWBT) and Fraunhofer IZI Announce Milestones Reached More...
• Cerus Corporation (CERS) and New York Blood Center to Collaborate on Development of Novel Red Blood Cell Biologic Product with Improved Uniformity More...
• Amgen (AMGN) Founding CEO George Rathmann Dies More...
• The New Amgen (AMGN) CEO and the Challenges He Faces, Must Win Investors With Payouts, Deals: Analysts More...
• S1 Pharmaceuticals, Inc. Announces New Executive Management and Scientific Advisory Board Appointments More...
• BioScrip (BIOS) Appoints Hai V. Tran as Senior Vice President, Chief Financial Officer and Treasurer More...
• miRagen Therapeutics Expands Executive Team Adding Drug Development Veteran More...
• Novartis AG (NVS) Quarterly Profit Drops as Diovan, OTC Sales Slump More...
• Alexion Pharmaceuticals Inc. (ALXN) Reports First Quarter 2012 Results More...
• Array BioPharma, Inc. (ARRY) to Report Financial Results for the Third Quarter of Fiscal 2012 on April 30, 2012 More...
• Astex Pharmaceuticals (ASTX) to Announce 2012 First Quarter Financial Results on April 30, 2012 More...
• Aegerion Pharmaceuticals, Inc. to Announce First Quarter 2012 Financial Results on Tuesday, May 1 More...
More Earnings Report News
• The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in NeurogesX, Inc. (NGSX) of Class Action Lawsuit More...
More Legal News
• Life Technologies (LIFE) to Build Additional $20 Million State of the Art Cell Culture Facility in Scotland More...
• AAIPharma Services Opens New Technology Center More...
• PsiOxus Therapeutics Limited Moves into New Facilities on Milton Park to Accommodate Expansion More...
• Affymax, Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Release: OMONTYS® (Peginesatide) Injection Now Available for Adult Chronic Kidney Disease (CKD) Patients on Dialysis in the United States More...
• Mylan Inc. (MYL) Launches Generic Version of Zyprexa® Tablets More...
• Vertex Pharmaceuticals (MA) (VRTX) Release: INCIVEK (telaprevir) Now Funded for People With Hepatitis C in Quebec and Saskatchewan More...
• Dr. Reddy's Laboratories Ltd. (RDY)'s Announces the Launch of Olanzapine Tablets More...
• Ikaria Inc.'s LUCASSIN® Approved in Australia More...
• Alimera Sciences (ALIM) Release: ILUVIEN® Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema More...
• Biogen Idec, Inc. (Massachusetts) (BIIB) Says Phase III Data Highlight Safety Profile For BG-12 MS Drug; Stock Rises +Up 2.14(1.70%) @ 1:22PM EDT More...
• Sosei Group Corporation's QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149 More...
• Nordion International Announces Europe-Focused Phase III Clinical Trial for TheraSphere® Liver Cancer Treatment More...
• RedHill Biopharma Ltd. Commences a Pivotal Bioequivalence Trial with RHB-103 (An Oral Thin Film for the Treatment of Migraine); Subjects' Recruitment Completed; First Dose Administered; Results Expected within Months More...
• Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Continue Falk Phase 2 Trial of TSO in Crohn's Disease More...
• Evidence Behind Autism Drugs May Be Biased, University of Michigan Study More...
• Could Caffeine Help Dry Eye? University of Tokyo School of Medicine Study More...
• How to Look Good on Facebook, University of Twente Study More...
• PURE Bioscience (PURE) Announces Positive Research from University of Arkansas More...
• Advanced Cell Technology Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt's Disease Patients in U.S. Trial More...
• NewLink Genetics Receives Notice of Allowance From USPTO for New Patent Broadly Covering Its D-1MT IDO Pathway Inhibitor More...
• MediciNova, Inc. Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain More...
• Merck KGaA (MKGAF.PK) Slashes 580 Jobs Amid Swiss HQs Shutdown More...
• Unipharma to Add 44 Jobs in New York More...
• Argos Therapeutics, Inc. Raises $25 Million Series D Financing More...
• miRagen Therapeutics Secures $20 Million Series B Financing More...
• Watson Pharmaceuticals, Inc. (WPI) May Pay $6 Billion Actavis More...
• Bausch & Lomb and ISTA Pharmaceuticals, Inc. (ISTA) Announce Early Termination of Hart-Scott-Rodino Waiting Period More...
• IMS Health (RX) Expands Services in Pharma R&D With Acquisition of DecisionView More...
• US Clinical Laboratories Announces Houston Acquisition More...
• Bayer AG (BAY.F) to Develop Cancer Treatment With Amgen (AMGN) More...
• ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development More...
• Sandoz, Inc. Enters Local Cameroon Production Partnership to Increase Access to Quality Medicines in Sub-Saharan Africa More...
• Northwest Biotherapeutics (NWBT) and Fraunhofer IZI Announce Milestones Reached More...
• Cerus Corporation (CERS) and New York Blood Center to Collaborate on Development of Novel Red Blood Cell Biologic Product with Improved Uniformity More...
• Amgen (AMGN) Founding CEO George Rathmann Dies More...
• The New Amgen (AMGN) CEO and the Challenges He Faces, Must Win Investors With Payouts, Deals: Analysts More...
• S1 Pharmaceuticals, Inc. Announces New Executive Management and Scientific Advisory Board Appointments More...
• BioScrip (BIOS) Appoints Hai V. Tran as Senior Vice President, Chief Financial Officer and Treasurer More...
• miRagen Therapeutics Expands Executive Team Adding Drug Development Veteran More...
• Novartis AG (NVS) Quarterly Profit Drops as Diovan, OTC Sales Slump More...
• Alexion Pharmaceuticals Inc. (ALXN) Reports First Quarter 2012 Results More...
• Array BioPharma, Inc. (ARRY) to Report Financial Results for the Third Quarter of Fiscal 2012 on April 30, 2012 More...
• Astex Pharmaceuticals (ASTX) to Announce 2012 First Quarter Financial Results on April 30, 2012 More...
• Aegerion Pharmaceuticals, Inc. to Announce First Quarter 2012 Financial Results on Tuesday, May 1 More...
More Earnings Report News
• The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in NeurogesX, Inc. (NGSX) of Class Action Lawsuit More...
More Legal News
• Life Technologies (LIFE) to Build Additional $20 Million State of the Art Cell Culture Facility in Scotland More...
• AAIPharma Services Opens New Technology Center More...
• PsiOxus Therapeutics Limited Moves into New Facilities on Milton Park to Accommodate Expansion More...